Ocular Surface Disease Spotlight

Click here to watch the video version of this podcast.

Today’s podcast shines the spotlight on the front of the eye, focusing new treatments and approaches to dry eye disease, blepharitis, and Sjogren’s Syndrome, to name a few.

Kelly Nichols, OD, PhD, dean of the University of Alabama at Birmingham School of Optometry, guides a panel of four clinical and industry experts through a robust conversation on ocular surface disease.

They start by sharing their optimism around new treatments and awareness initiatives. Jeffrey Nau, PhD, president of the newly formed Viatris Eye Care Division, said progress is inching along now, but “it’s only a matter of time until we have a massive uplift that will completely change the way we look at ocular surface disease.”

In late 2021, the FDA approved Tyrvaya, the first nasal spray for dry eye disease. Researchers continue to evaluate treatments and diagnostics from multiple angles. Physicians continue to tailor their approaches to better educate, diagnose, and treat ocular surface disease patients. What’s next?

Listen to the podcast today to hear the panelists discuss these and other topics, including:

• What excites you about current and emerging eye care innovations?
• What’s your approach for both new and returning dry eye patients?
• What’s your typical patient intake workflow?
• How much time do you spend educating dry eye patients?
• How important are companion diagnostics in ocular surface disease?

[Press Play to Listen]

Participants:
Douglas Devries, OD—Eye Care Associates of Nevada
Selina McGee, OD—CEO & Owner, BeSpoke Vision; president, Intrepid Eye Society
Jeffrey Nau, PhD—President, Viatris Eye Care Division
Kelly Nichols, OD, MPH, PhD—Dean and Professor, School of Optometry, The University of Alabama at Birmingham, Ocular Surface Research Institute of the Clinical Eye Research Facility (moderator)
Leslie O’Dell, OD—Medical Optometry America